Advertisement

Topics

Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance

19:00 EST 28 Feb 2017 | Globe Newswire

- Q4 2016 Revenue Increase to $284 Million -

- Q4 2016 GAAP Diluted EPS Decrease of 4% to $0.26; Q4 2016 Adjusted Diluted EPS Decrease of 3% to $0.58 -

- FY 2016 Revenue Increase of 13% to $1,117 Million -

- FY 2016 GAAP Diluted EPS Increase of 20% to $1.47; FY 2016 Adjusted Diluted EPS Increase of 11% to $2.25 -

- Conference Call and Webcast to Be Held March 1, 2017 at 10:00 a.m. EST -

LAKE FOREST, Ill., March 01, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the fourth quarter 2016 and full year 2016, and provided full year 2017 guidance.

Q4 2016 Operating Highlights:

  • Received three Abbreviated New Drug Application (“ANDAs”) approvals:
    - Ibuprofen 100mg/5mL Oral Suspension that launched in November 2016
    - Azelastine Hydrochloride Ophthalmic Solution, 0.05% that launched in January 2017
    - Triamcinolone Acetonide Topical Aerosol, 0.147 mcg/mL that the Company is planning to launch in 2017 
  • Expanded R&D footprint with October opening of new R&D center in Cranbury, NJ
  • Submitted 12 ANDAs to the Food and Drug Administration ("FDA")
  • Received favorable ruling from the Patent Trial and Appeal Board ("PTAB") in the inter partes review (IPR) proceeding finding all of the claims of the Durezol® patent to be obvious; the decision has subsequently been appealed as expected
  • Received FDA NAI status (No Action Indicated), the highest status level available, for the Company's Decatur facility, following the December 2016 re-inspection.  The Company's three other FDA approved manufacturing sites are in good standing following 2016 FDA inspections.
  • Made significant progress at Akorn India; on track with plan to resume exhibit batch production in Q3 2017

Raj Rai, Akorn’s Chief Executive Officer, commented, “We are pleased with our performance in 2016. First and foremost, we completed the restatement of our 2014 financials and became current with our SEC filings, which in itself was a major accomplishment.  In 2016, we achieved record revenues, surpassing a billion dollars and solidifying Akorn’s position among the top specialty generics companies with manufacturing roots in the United States. This would not have happened without the collective efforts and dedication of all Akorn employees.”

Rai further added, “Our focus in 2017 and beyond remains consistent with our growth strategy of diversifying our portfolio, thus reducing product concentration through harvesting and replenishing our pipeline, deploying capital to consummate smart acquisitions through business development efforts and continuing to invest in our infrastructure. Finally, we remain optimistic about both the short and long-term prospects of our business despite the headwinds in our industry.”

Summary Financial Results for the Quarter Ended December 31, 2016:

Akorn reported revenues of $284 million for the fourth quarter 2016 representing an increase of $4 million, or 1%, over the fourth quarter 2015. Full year 2016 revenues of $1,117 million represented an increase of $132 million, or 13.4%, over prior year revenues of $985 million.

GAAP net income for the fourth quarter 2016 was $32 million, or $0.26 per diluted share, compared to GAAP net income of $33 million, or $0.27 per diluted share, in the same quarter of 2015. Including a net adjustment of $40 million to net income for non-GAAP items, adjusted diluted earnings per share were $0.58 in the fourth quarter 2016, compared to a net adjustment of $43 million to net income for non-GAAP items and adjusted diluted earnings per share of $0.60 in the same quarter 2015.  For information regarding adjusted diluted earnings per share and other non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

GAAP net income for the full year 2016 was $184 million, or $1.47 per diluted share, compared to GAAP net income of $151 million, or $1.22 per diluted share, in the prior year. Including a net adjustment of $99 million to net income for non-GAAP items, adjusted diluted earnings per share were $2.25 in 2016, compared to a net adjustment of $103 million to net income for non-GAAP items and adjusted diluted earnings per share of $2.02 in the prior year ended December 31, 2015.

The 2016 results included the impact of the adoption of ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” that requires the income tax benefit from employee stock option exercises to be recognized through the income tax provision in the period the stock options are exercised.  Previously, this benefit was recognized directly to equity.  For the fourth quarter 2016, the Company had an insignificant impact in the income tax provision and no impact to the diluted earnings per share from employee stock option exercises.  For the full year 2016, the Company recognized an aggregate $11.4 million tax benefit, or $0.09 per diluted share, from employee stock option exercises.  There was no change to the income tax provision for 2015 as the adoption impacts current and future periods.  The full year 2016 adjusted diluted earnings per share excluded the $0.09 per diluted share tax benefit from employee stock option exercises.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was $112 million in the fourth quarter 2016, compared to $115 million in the fourth quarter 2015.  EBITDA was $442 million in the full year 2016, compared to $401 million in the prior year. Adjusted EBITDA, which is another non-GAAP measure used by management to evaluate the continuing operations of the Akorn business, was $125 million in the fourth quarter 2016, compared to $135 million in the fourth quarter 2015.  Adjusted EBITDA was $509 million in the full year 2016, compared to $460 million in the prior year.  For information regarding EBITDA, Adjusted EBITDA and other non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

As of the year ended December 31, 2016, Akorn had a trailing twelve months net debt to adjusted EBITDA ratio of 1.2x.  For information regarding net debt, net debt to adjusted EBITDA ratio and other non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

2017 Guidance:

The following table provides Akorn’s 2017 guidance; see assumptions below. In millions, except gross margin percentage, income tax rate and per share amounts.

  2017 Guidance
  Lower Range Upper Range
Consolidated revenue, net $1,010  $1,060 
Consolidated gross margin percentage 54% 55%
SG&A expense (GAAP) 258  258 
SG&A expense (Non-GAAP) 161  161 
R&D expense (GAAP) 44  44 
R&D expense (Non-GAAP) 43  43 
Non-Operating Expenses (GAAP) 43  43 
Non-Operating Expenses (Non-GAAP) 38  38 
Income tax rate 37% 37%
GAAP net income 124  148 
Adjusted net income (Non-GAAP) 191  215 
GAAP net income per diluted share 0.99  1.18 
Adjusted net income per diluted share (Non-GAAP) 1.53  1.72 
EBITDA (Non-GAAP) 320  358 
Adjusted EBITDA (Non-GAAP) 363  401 
Operating cash flows 250  275 
Capital Expenditures 70  90 
Fully Diluted Shares Outstanding 125  125 

2017 Assumptions:

  • New product approvals.  Akorn's guidance includes $30 to $60 million from new product launches of products already approved and those expected to be approved in 2017.  The Company expects the majority of these revenues will be generated in the second half of the year.
  • Ephedrine Sulfate Injection.  Akorn’s guidance contemplates two competitors for the remainder of 2017 and that Akorn will retain 30%-35% of the market.

For information regarding non-GAAP financial measures, see “Non-GAAP Financial Measures” below.

R&D Update:

At February 15, 2017, Akorn had 90 ANDAs pending at the FDA, representing approximately $9.5 billion in annual branded and generic market value according to IMS Health. Akorn has 75 additional ANDAs in various stages of development, representing approximately $13 billion in annual branded and generic market value according to IMS Health.

Status of Akorn Pending ANDA Filings, February 15, 2017:

Filed Age  Tentative< 24 Months24 - 36 Months> 36 MonthsTotal
values in millions Count Value *Count Value *Count Value *Count Value *Count Value *
Ophthalmic  Brand 6 $9963 $2752 $2796 $3,19417 $4,744
 Generic     3  1986  969  294
InjectableBrand 1  4911  572  241  2915  863
 Generic 1  612  5605  1,36816  46634  2,400
TopicalBrand   1  61  13  2  19
 Generic   6  4943  2342  4711  775
OtherBrand           
 Generic   5  2612  845  8412  429
Total  8 $1,49328 $1,65318 $2,20036 $4,17890 $9,524

* The IMS market value, shown in millions, is based on the IMS data for the trailing 12 months ended December 31, 2016 and excludes any trade and customary allowances and discounts. The addressable IMS market value figures presented in this press release outline the approximate aggregate size of the potential market, as estimated by IMS Health, and are not forecasts of our future sales.

Stock Repurchase Utilization:

During the quarter ended December 31, 2016, the Company repurchased a total of approximately 0.9 million shares at an average price of $22.06 per share of common stock and has $155 million repurchase availability remaining. The timing and the amount of any additional repurchases would be determined by the Company’s management based on its evaluation of market conditions, acquisition opportunities, capital allocation alternatives, and other factors.

Conference Call and Webcast Details:

As previously announced, Akorn’s management will hold a conference call with interested investors and analysts at 10:00 a.m. EST on March 1, 2017 to discuss these results and updates in more detail. The dial-in number to access the call is (844) 249-9382 in the U.S. and Canada and (270) 823-1530 for international callers. The conference ID is 62420433. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

About Akorn:

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Non-GAAP Financial Measures:

To supplement Akorn’s financial results and guidance presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP (also referred to as “adjusted” or “non-GAAP adjusted”) financial measures in this press release and the accompanying tables, including (1) EBITDA, (2) adjusted EBITDA, (3) adjusted net income, (4) adjusted diluted earnings per share, (5) net debt, (6) net debt to adjusted EBITDA ratio, (7) adjusted tax and (8) adjusted tax rate.

The Company believes that adjusted net income and adjusted diluted earnings per share are meaningful financial indicators, to both Company management and investors, in that they exclude non-cash income and expense items that have no impact on current or future cash flows, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.  Akorn’s management uses EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share in managing and analyzing its business and financial condition and setting performance goals.  Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash or non-recurring operating expenses that have no impact on continuing cash flows as well as other items that are not expected to recur and therefore are not reflective of continuing operating performance.  The Company uses net debt and net debt to EBITDA ratio to analyze the financial capacity for further leverage and in analyzing the business and financial condition. Adjusted tax and adjusted tax rate are utilized as management believes it adds comparability through the elimination of discrete tax events which are unrelated to the continuing cash flows of the Company. Akorn’s management believes that the presentation of these and other non-GAAP financial measures provide investors greater transparency into Akorn’s ongoing results of operations allowing investors to better compare the Company’s results from period to period.  See “Reconciliation of Non-GAAP Financial Measures” attached for details regarding the adjustments made.

The shortcomings of non-GAAP financial measures as guidance or performance measures are that they provide a view of the Company’s results of operations without including all events during a period. For example, Adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense. Adjusted net income does not take into account non-cash expenses that reflect the amortization of past expenditures, or include share-based compensation, which is an important and material element of the Company's compensation package for its directors, officers and other key employees.

Investors should also note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time-to-time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Because of the non-standardized definitions, the non-GAAP financial measures as used by Akorn in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies.

Due to the inherent limitations of non-GAAP financial measures, investors should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.  See “Reconciliation of Non-GAAP Financial Measures” attached.

Forward Looking Statements

This press release includes statements that may constitute "forward looking statements"  including our 2017 financial guidance; assumptions related to our guidance, including statements regarding product approvals, launches, competition, market share and other market conditions; statements about our portfolio of ANDAs both pending at the FDA and in other, earlier stages of development; statements regarding market values and Akorn's planned launches and regulatory approvals; and statements regarding the timing and amount of additional share repurchases. When used in this document, the words “anticipate,” "plan," "will," "continue," "contemplate," "could," “believe,” “estimate” and “expect” and similar expressions are generally intended to identify forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Factors that could cause or contribute to such differences include, but are not limited to: the difficulty of predicting the impact of the restatement on our future financial results; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the susceptibility of our generic and off patent pharmaceutical products to competition, substitution policies and reimbursement policies of the government; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations; the continuing consolidation of our customer base, which could adversely affect sales of our products; our dependence on a small number of distributors, the loss of any of which could have a material adverse effect; changes in the laws and regulations and such other risks and uncertainties outlined in the "Risk Factors" section of Akorn's Form 10-K and any subsequent filings with the SEC. Except as expressly required by law, Akorn disclaims any intent or obligation to update any forward-looking statements herein.

Trademarks mentioned are the property of their respective owners.

 
AKORN, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In Thousands, Except Per Share Data)
 
 Three Months Ended
December 31,
 Year Ended
December 31,
 2016 2015 2016 2015
REVENUES$283,667  $279,977  $1,116,843  $985,076 
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)114,413  105,547  442,572  389,064 
GROSS PROFIT169,254  174,430  674,271  596,012 
        
Selling, general and administrative expenses47,370  51,980  197,501  162,205 
Acquisition-related costs8  129  364  1,841 
Research and development expenses13,638  10,404  42,603  40,707 
Amortization of intangible assets16,291  17,066  65,713  66,272 
Impairment of intangible assets31,151  30,376  40,519  30,376 
TOTAL OPERATING EXPENSES108,458  109,955  346,700  301,401 
OPERATING INCOME60,796  64,475  327,571  294,611 
Amortization of deferred financing costs(1,304) (1,175) (10,791) (4,283)
Interest expense, net(10,104) (12,606) (42,734) (51,973)
Bargain purchase gain      849 
Other non-operating expense, net(149) (1,239) (2,746) (7,048)
        
INCOME BEFORE INCOME TAXES49,239  49,455  271,300  232,156 
Income tax provision16,784  16,670  87,057  81,358 
        
CONSOLIDATED NET INCOME$32,455  $32,785  $184,243  $150,798 
CONSOLIDATED NET INCOME PER SHARE:       
CONSOLIDATED NET INCOME PER SHARE, BASIC$0.26  $0.27  $1.50  $1.29 
CONSOLIDATED NET INCOME PER SHARE, DILUTED$0.26  $0.27  $1.47  $1.22 
        
SHARES USED IN COMPUTING NET INCOME PER SHARE:       
BASIC124,765  119,390  122,869  116,980 
DILUTED125,050  125,698  125,801  125,762 
        
COMPREHENSIVE INCOME:       
Consolidated net income$32,455  $32,785  $184,243  $150,798 
Unrealized holding gain (loss) on available-for-sale securities(23) 191  740  104 
Foreign currency translation gain (loss)(2,778) (632) (1,941) (2,051)
Pension liability adjustment (loss) gain(1,058)   (3,624)  
COMPREHENSIVE INCOME$28,596  $32,344  $179,418  $148,851 


AKORN, INC. 
CONSOLIDATED BALANCE SHEETS 
(In Thousands, Except Share Data)
 
 December 31,
 2016 2015
ASSETS   
CURRENT ASSETS   
Cash and cash equivalents$200,772  $346,266 
Trade accounts receivable, net283,154  150,621 
Inventories, net174,793  185,316 
Available-for-sale securities1,106  5,941 
Prepaid expenses and other current assets25,986  19,988 
TOTAL CURRENT ASSETS685,811  708,132 
PROPERTY, PLANT AND EQUIPMENT, NET238,404  179,614 
OTHER LONG-TERM ASSETS   
Goodwill284,293  284,710 
Intangible assets, net
758,854  864,989 
Deferred tax assets5,286  4,207 
Long-term investments9  129 
Other non-current assets1,063  764 
TOTAL OTHER LONG-TERM ASSETS1,049,505  1,154,799 
TOTAL ASSETS$1,973,720  $2,042,545 
LIABILITIES AND SHAREHOLDERS’ EQUITY   
CURRENT LIABILITIES   
Trade accounts payable$59,534  $46,019 
Purchase consideration payable4,994  4,967 
Income taxes payable16,198  23,670 
Accrued royalties15,044  19,378 
Accrued compensation19,113  15,866 
Current maturities of long-term debt (net of current deferred financing costs)  52,779 
Accrued administrative fees36,436  37,094 
Accrued expenses and other liabilities24,236  31,603 
TOTAL CURRENT LIABILITIES175,555  231,376 
LONG-TERM LIABILITIES   
Long-term debt (net of non-current deferred financing costs)809,979  994,033 
Deferred tax liability157,607  188,808 
Other long-term liabilities11,395  6,763 
TOTAL LONG-TERM LIABILITIES978,981  1,189,604 
TOTAL LIABILITIES1,154,536  1,420,980 
SHAREHOLDERS’ EQUITY   
Common stock, no par value — 150,000,000 shares authorized; 124,390,217 and 119,427,471 shares issued and outstanding at December 31, 2016 and 2015521,860  458,659 
Retained earnings319,291  180,048 
Accumulated other comprehensive loss(21,967) (17,142)
TOTAL SHAREHOLDERS’ EQUITY819,184  621,565 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$1,973,720  $2,042,545 


AKORN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
  
 Year ended December 31,
 2016 2015
OPERATING ACTIVITIES:   
Consolidated net income$184,243  $150,798 
Loss from discontinued operations, net of tax   
Adjustments to reconcile consolidated net income to net cash provided by operating activities:   
Depreciation and amortization87,963  86,924 
Impairment of intangible assets44,369  33,003 
Amortization of deferred financing fees10,760  4,350 
Amortization of favorable (unfavorable) contracts  71 
Amortization of inventory step-up  4,681 
Non-cash stock compensation expense15,412  12,997 
Non-cash interest expense777  2,778 
Non-cash gain on bargain purchase  (849)
Gain from product divestiture   
Deferred income taxes, net(32,934) (46,130)
Excess tax benefit from stock compensation  (47,997)
Loss on extinguishment of debt  1,243 
Gain (loss) on sale of available-for-sale security45  237 
Other(4,888)  
Changes in operating assets and liabilities:   
Trade accounts receivable, net(132,617) 40,287 
Inventories, net10,208  (50,729)
Prepaid expenses and other current assets(6,494) 17,574 
Trade accounts payable6,139  (4,819)
Accrued expenses and other liabilities(15,224) 93,229 
NET CASH PROVIDED BY OPERATING ACTIVITIES167,759  297,648 
INVESTING ACTIVITIES:   
Payments for acquisitions and equity investments, net of cash acquired  (24,408)
Proceeds from disposal of assets5,966  2,459 
Payments for other intangible assets(3,950) (3,835)
Purchases of property, plant and equipment(74,938) (27,934)
NET CASH USED IN INVESTING ACTIVITIES(72,922) (53,718)
FINANCING ACTIVITIES:   
Proceeds under stock option and stock purchase plans9,795  11,916 
Payments of contingent acquisition liabilities  (8,991)
Debt financing costs(5,128) (8,564)
Excess tax benefits from stock compensation  47,997 
Common stock repurchases(45,000)  
Debt repayment(200,000) (10,450)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES(240,333) 31,908 
Effect of changes in exchange rates on cash and cash equivalents2  (251)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS(145,494) 275,587 
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR346,266  70,679 
CASH AND CASH EQUIVALENTS AT END OF YEAR$200,772  $346,266 


AKORN, INC. 
Reconciliation of Non-GAAP Financial Measures

Due to the inherent limitations of non-GAAP financial measures, investors should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, measures of financial performance prepared in accordance with GAAP.  Set forth on the following tables are reconciliations of each non-GAAP financial measure used in this press release to the most directly comparable GAAP financial measure.

AKORN, INC.
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
(In Thousands)
 
 Three Months Ended Year Ended
  December 31, December 31,
  2016 2015 2016 2015
NET INCOME$32,455  $32,785  $184,243  $150,798 
         
ADJUSTMENTS TO ARRIVE AT EBITDA:       
 Depreciation expense5,672  5,491  22,220  19,939 
 Amortization expense16,291  17,066  65,713  66,272 
 Impairment expense31,151  30,376  40,519  30,376 
 Interest expense, net10,097  12,153  41,713  49,029 
 Non-cash interest expense7  453  1,021  2,944 
 Income tax provision16,784  16,670  87,057  81,358 
EBITDA$112,457  $114,994  $442,486  $400,716 
         
NON-CASH AND OTHER NON-RECURRING INCOME AND EXPENSES       
 Acquisition-related expenses8  129  364  1,841 
 Non-cash stock compensation expense4,130  3,726  15,412  13,198 
 Bargain purchase gain      (849)
 Loss from asset sales16    54  369 
 Amortization of inventory step-up      4,681 
 Debt financing costs1,304  1,175  10,791  4,283 
 Restatement Expense3,474  12,572  34,226  27,444 
 Loss on impairment3,645  460  2,906  3,087 
 Executive bonus clawback    (1,087)  
 Litigation settlement294  1,519  3,824  5,569 
ADJUSTED EBITDA$125,328  $134,575  $508,976  $460,339 


AKORN, INC.
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income
(In Thousands, Except Per Share Data)
    
 Three Months Ended Year Ended
 December 31, December 31,
 2016 2015 2016 2015
NET INCOME$32,455  $32,785  $184,243  $150,798 
        
INCOME TAX PROVISION16,784  16,670  87,057  81,358 
        
INCOME BEFORE INCOME TAXES$49,239  $49,455  $271,300  $232,156 
        
ADJUSTMENTS TO ARRIVE AT ADJUSTED NET INCOME:       
Acquisition-related expenses (1)8  129  364  1,841 
Restatement expenses (2)3,474  12,572  34,226  27,444 
Non-cash stock compensation expense (2, 3, 4)4,130  3,726  15,412  13,198 
Non-cash interest expense (5)7  453  1,021  2,944 
Amortization expense (6)16,291  17,066  65,713  66,272 
Loss from asset sales (5)16    54  369 
Bargain purchase gain (5)      (849)
Intangible impairment (7)31,151  30,376  40,519  30,376 
Amortization of inventory step-up (4)      4,681 
Debt financing costs (5)1,304  1,175  10,791  4,283 
Loss on impairment (3)3,645  460  2,906  3,087 
Executive Bonus Clawback (8)    (1,087)  
Litigation settlement (5)294  1,519  3,824  5,569 
        
ADJUSTED INCOME BEFORE INCOME TAX$109,559  $116,931  $445,043  $391,371 
        
Option exercise tax impact (9)(597)   11,395   
ADJUSTED INCOME TAX PROVISION37,838  40,921  150,111  137,155 
TOTAL ADJUSTED INCOME TAX PROVISION$37,241  $40,921  $161,506  $137,155 
        
ADJUSTED NET INCOME$72,318  $76,010  $283,537  $254,216 
        
ADJUSTED DILUTED EARNINGS PER SHARE (10)$0.58  $0.60  $2.25  $2.02 
        
(1) - Excluded from acquisition-related expenses
(2) - Excluded from S,G & A expenses
(3) - Excluded from R&D expenses
(4) - Excluded from cost of goods sold
(5) - Excluded from non-operating expenses
(6) - Excluded from amortization of intangibles
(7) - Excluded from impairment of intangibles
(8) - Excluded from other non-operating expenses, net
(9) - Included in income tax expense
(10) - Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period.


AKORN, INC.
Reconciliation of GAAP Debt to Non-GAAP Net Debt and Net Debt to Adjusted EBITDA Ratio
(In Thousands, Except Net Debt to Adjusted EBITDA Ratio)
  
 December 31, 2016
GAAP Debt$809,979 
Deferred financing costs21,959 
Total term loans outstanding$831,938 
Cash and cash equivalents200,772 
Net debt (1)$631,166 
  
Adjusted EBITDA, year ended$508,976 
  
Net debt to adjusted EBITDA ratio (2)1.2 

(1) Net debt, as defined by the Company, is gross debt including Akorn’s term loan and revolving debt balances (if applicable) less cash and cash equivalents.

(2) Net debt to Adjusted EBITDA ratio, as defined by the Company, is net debt divided by the trailing twelve months Adjusted EBITDA.


AKORN, INC.
Reconciliation of 2017 Financial Guidance of GAAP Net Income to Non-GAAP Adjusted Net Income and GAAP Net Income to Non-GAAP Adjusted EBITDA
(In Millions, Except Per Share Data)
 
Reconciliation of GAAP Net Income to NON-GAAP Adjusted Net Income: 
 2017 Guidance
 Lower Range Upper Range
GAAP Net Income$124  $148 
    
Add:   
Intangible and amortization expense63  63 
Share-based compensation expense21  21 
Amortization of deferred financing costs5  5 
Acquisition-related expenses and other adjustments17  17 
    
Subtract:   
Tax effect of adjustments(39) (39)
    
Adjusted net income$191  $215 
    
Adjusted diluted earnings per share$1.53  $1.72 
    
Fully Diluted Shares Outstanding125  125 
    
Reconciliation of GAAP Net Income to NON-GAAP Adjusted EBITDA 
 2017 Guidance
 Lower Range Upper Range
Net income$124  $148 
    
Add:   
Depreciation & amortization expense85  85 
Interest expense, net (cash & non-cash)38  38 
Income tax provision73  87 
EBITDA$320  $358 
    
Add:   
Share-based compensation21  21 
Amortization of deferred financing costs5  5 
Acquisition-related expenses and other adjustments17  17 
    
Adjusted EBITDA$363  $401 

 

Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
Stephanie.carrington@icrinc.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...